References
- WHO. [Cited 2021 Apr 17]. Available from: https://covid19.who.int/.
- Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.
- Lai CC, Wang CY, Wang YH, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55:105946.
- Huang WH, Teng LC, Yeh TK, et al. 2019 novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2020;53:481–484.
- Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53:365–367.
- Hsih WH, Cheng MY, Ho MW, et al. Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. J Microbiol Immunol Infect. 2020;53:459–466.
- Huang HT, Chen TC, Liu TY, et al. How to prevent outbreak of a hospital-affiliated dementia day-care facility in the pandemic COVID-19 infection in Taiwan. J Microbiol Immunol Infect. 2020;53:394–395.
- Krishnakumar B, Rana S. COVID 19 in India: strategies to combat from combination threat of life and livelihood. J Microbiol Immunol Infect. 2020;53:389–391.
- Lai CC, Wang JH, Ko WC, et al. COVID-19 in long-term care facilities: an upcoming threat that cannot be ignored. J Microbiol Immunol Infect. 2020;53:444–446.
- Yang CJ, Chen TC, Chen YH. The preventive strategies of community hospital in the battle of fighting pandemic COVID-19 in Taiwan. J Microbiol Immunol Infect. 2020;53:381–383.
- Yen MY, Schwartz J, Chen SY, et al. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts. J Microbiol Immunol Infect. 2020;53:377–380.
- Lai CC, Chen CH, Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;dkab093. DOI:https://doi.org/10.1093/jac/dkab093.
- Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis. J Infect. 2021;82:e34–e35.
- Chen PJ, Chao CM, Lai CC. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. J Infect. 2020. doi:https://doi.org/10.1016/j.jinf.2020.12.005
- Chen PL, Lee NY, Cia CT, et al. A review of treatment of coronavirus disease 2019 (COVID-19): therapeutic repurposing and unmet clinical needs. Front Pharmacol. 2020;11:584956.
- Cheng CY, Lee YL, Chen CP, et al. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020;53:488–492.
- Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53:436–443.
- Than HM, Nong VM, Nguyen CT, et al. Management of mild cases of COVID-19 in low-resource countries: an experience in Vietnam. J Microbiol Immunol Infect. 2021;54:139–140.
- Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595–1606.
- Singh JA, Upshur REG. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. Lancet Infect Dis. 2021;21:e103–e109.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403–416.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
- Benenson S, Oster Y, Cohen MJ, et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021;384:1775–1777.
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423.
- Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, First responders, and other essential and frontline workers - Eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:495–500.
- Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283–288.
- Amit S, Beni SA, Biber A, et al. Postvaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. 2021;27:1220–1222.
- European Medicines Agency. [Cited 2021 Apr 17]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
- Carli G, Nichele I, Ruggeri M, et al. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021;16:803–804.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–2101.
- Mehta PR, Mangion SA, Benger M, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - a report of two UK cases. Brain Behav Immun. 2021;95:514–517.
- Muir K-L, Kallam A, Koepsell SA, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384:1964–1965.
- Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–2130.
- Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202–2211.
- Taquet MHM, Geddes JR, Luciano S, et al. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. [Cited 2021 Apr 17]. Available from: https://osf.io/a9jdq/.
- D’Agostino V, Caranci F, Negro A, et al. A rare case of cerebral venous thrombosis and disseminated intravascular coagulation temporally associated to the COVID-19 vaccine administration. J Pers Med. 2021;11:285.
- Vaccine Adverse Event Reporting System (VAERS). [Cited 2021 Apr 25]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vaers.html.
- Bayas A, Menacher M, Christ M, et al. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet. 2021;397.
- Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254–2256.
- Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021. DOI: https://doi.org/10.1055/a-1469-7481.
- US CDC. [Cited 2021 Apr 25]. Available from: file:///C:/Users/Administrator/Downloads/03-COVID-Shimabukuro-508.pdf.
- Østergaard SD, Schmidt M, Horváth-Puhó E, et al. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021;397:1441–1443.
- Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114.
- Wolf ME, Luz B, Niehaus L, et al. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 Vaccine AstraZeneca” exposure. J Clin Med. 2021;10:1599.
- Greinacher A, Selleng K, Wesche J, et al.Towards understanding ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) [preprint]. 2021. doi:https://doi.org/10.21203/rs.3.rs-440461/v1.
- WHO. [Cited 2021 Apr 18]. Available from: https://www.who.int/news/item/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)
- McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-Induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021;121:102662.
- International Society on Thrombosis and Haemostasis. [Cited 2021 Apr 21]. Available from: https://cdn.ymaws.com/www.isth.org/resource/resmgr/ISTH_VITT_Guidance_2.pdf.
- US CDC. [Cited 2021 Apr 18]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html.
- U.S. Food and Drug Administration. [Cited 2021 Apr 24]. Available from: https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough.
- European Medicines Agency. [Cited 2021 Apr 21]. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-provide-further-context-risk-very-rare-blood-clots-low-blood
- European Medicines Agency. [Cited 2021 Apr 21]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
- Brighton Collaboration. [Cited 2021 Apr 25]. Available from: https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v9.0-April-16-202115853.pdf.
- Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646–1657
- Fabiani M, Ramigni M, Gobbetto V, et al. Effectiveness of the comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill. 2021;26(17). DOI:https://doi.org/10.2807/1560-7917.ES.2021.26.17.2100420
- Li X, Ostropolets A, Makadia R, et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study. medRxiv. 2021;2021. DOI:https://doi.org/10.1101/2021.03.25.21254315.
- MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(17):651–656.